Melflufen-话题@MedSci

[GetTopicListResponse(id=1652653, encodeId=f618165265399, content=<a href='/topic/show?id=1c8b115325e' target=_blank style='color:#2F92EE;'>#Melflufen#</a>, objectTitle=Lancet Haematol：Melflufen联合地塞米松治疗复发性或难治性多发性骨髓瘤, objectType=article, longId=295220, objectId=fab329522003, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fab329522003, replyNumber=0, likeNumber=65, createdTime=2022-12-30, rootId=0, userName=xzw121, userId=cdd924313836, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fab329522003, moduleTitle=Lancet Haematol：Melflufen联合地塞米松治疗复发性或难治性多发性骨髓瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fab329522003)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652652, encodeId=9bc216526525d, content=<a href='/topic/show?id=1c8b115325e' target=_blank style='color:#2F92EE;'>#Melflufen#</a>, objectTitle=FDA优先审评多肽-药物偶联物（PDC）Melflufen治疗难治性多发性骨髓瘤的申请, objectType=article, longId=200078, objectId=465a2000e861, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=465a2000e861, replyNumber=0, likeNumber=63, createdTime=2020-09-26, rootId=0, userName=xzw121, userId=cdd924313836, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=465a2000e861, moduleTitle=FDA优先审评多肽-药物偶联物（PDC）Melflufen治疗难治性多发性骨髓瘤的申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=465a2000e861)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652650, encodeId=030f1652650ca, content=<a href='/topic/show?id=1c8b115325e' target=_blank style='color:#2F92EE;'>#Melflufen#</a>, objectTitle=抗癌肽-药物偶联物Melflufen治疗复发难治性多发性骨髓瘤, objectType=article, longId=190779, objectId=47c6190e7984, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=47c6190e7984, replyNumber=0, likeNumber=72, createdTime=2020-09-16, rootId=0, userName=xzw121, userId=cdd924313836, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=47c6190e7984, moduleTitle=抗癌肽-药物偶联物Melflufen治疗复发难治性多发性骨髓瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=47c6190e7984)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652651, encodeId=6487165265134, content=<a href='/topic/show?id=1c8b115325e' target=_blank style='color:#2F92EE;'>#Melflufen#</a>, objectTitle=EHA 2020：新型抗癌肽-药物偶联物Melflufen治疗难治性多发性骨髓瘤，2期HORIZON试验成功, objectType=article, longId=195934, objectId=4fce19593460, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4fce19593460, replyNumber=0, likeNumber=0, createdTime=2021-01-15, rootId=0, userName=xzw121, userId=cdd924313836, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4fce19593460, moduleTitle=EHA 2020：新型抗癌肽-药物偶联物Melflufen治疗难治性多发性骨髓瘤，2期HORIZON试验成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4fce19593460)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652649, encodeId=d7c11652649cd, content=<a href='/topic/show?id=1c8b115325e' target=_blank style='color:#2F92EE;'>#Melflufen#</a>, objectTitle=第24届EHA大会：Melflufen治疗复发难治多发性骨髓瘤的全新阳性数据, objectType=article, longId=168709, objectId=d348168e091c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d348168e091c, replyNumber=0, likeNumber=97, createdTime=2019-09-01, rootId=0, userName=xzw121, userId=cdd924313836, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d348168e091c, moduleTitle=第24届EHA大会：Melflufen治疗复发难治多发性骨髓瘤的全新阳性数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d348168e091c)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

Melflufen

2020-05-29

xzw121 (审核中...)

前往app查看评论内容

#Melflufen#

Lancet Haematol：Melflufen联合地塞米松治疗复发性或难治性多发性骨髓瘤

2022-12-30

xzw121 (审核中...)

前往app查看评论内容

#Melflufen#

FDA优先审评多肽-药物偶联物（PDC）Melflufen治疗难治性多发性骨髓瘤的申请

2020-09-26

xzw121 (审核中...)

前往app查看评论内容

#Melflufen#

抗癌肽-药物偶联物Melflufen治疗复发难治性多发性骨髓瘤

2020-09-16

xzw121 (审核中...)

前往app查看评论内容

#Melflufen#

EHA 2020：新型抗癌肽-药物偶联物Melflufen治疗难治性多发性骨髓瘤，2期HORIZON试验成功

2021-01-15

xzw121 (审核中...)

前往app查看评论内容

#Melflufen#

第24届EHA大会：Melflufen治疗复发难治多发性骨髓瘤的全新阳性数据

2019-09-01

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

#Melflufen#

科室

工具

服务